Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BPX-501 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BPX-501 | Rivogenlecleucel | BPX-501 (Rivogenlecleucel) comprises allogeneic T-cells transduced with a vector encoding inducible Casp9 that is linked to a drug binding domain, which enables induction of Casp9 with AP1903 if GVHD develops, resulting increased Casp9 expression and induction of T-cell death (PMID: 29343836). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03807063 | Phase I | Rimiducid BPX-501 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | Withdrawn | USA | 0 |
NCT02065869 | Phase Ib/II | BPX-501 Rimiducid | Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant | Active, not recruiting | 2 | |
NCT02487459 | Phase I | BPX-501 Rimiducid | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | Withdrawn | USA | 0 |
NCT02786485 | Phase I | Rimiducid BPX-501 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | Withdrawn | 0 | |
NCT01744223 | Phase Ib/II | Rimiducid BPX-501 | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | Active, not recruiting | USA | 0 |